Nelson Sun Buys 6,000 Shares of Aardvark Therapeutics (NASDAQ:AARD) Stock

Key Points

• Aardvark Therapeutics CFO Nelson Sun purchased 6,000 shares of the company's stock at an average cost of $8.07 per share, increasing his total ownership to approximately 105,484 shares.
• The company's stock recently traded at $8.00, with a 12-month price range of $4.88 to $19.58.
• Aardvark Therapeutics reported an earnings miss, with an EPS of ($0.66), falling short of the consensus estimate of ($0.52).

Aardvark Therapeutics, Inc. (NASDAQ:AARD - Get Free Report) CFO Nelson Sun purchased 6,000 shares of Aardvark Therapeutics stock in a transaction dated Tuesday, September 9th. The shares were purchased at an average cost of $8.07 per share, for a total transaction of $48,420.00. Following the transaction, the chief financial officer owned 105,484 shares in the company, valued at approximately $851,255.88. This trade represents a 6.03% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Aardvark Therapeutics Stock Up 15.8%

NASDAQ AARD traded up $1.36 on Monday, reaching $9.95. The stock had a trading volume of 562,695 shares, compared to its average volume of 162,758. Aardvark Therapeutics, Inc. has a 12-month low of $4.88 and a 12-month high of $19.58. The stock has a fifty day moving average price of $10.88 and a two-hundred day moving average price of $10.51.

Aardvark Therapeutics (NASDAQ:AARD - Get Free Report) last announced its earnings results on Wednesday, August 13th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.52) by ($0.14).

Analysts Set New Price Targets

AARD has been the topic of a number of recent research reports. Royal Bank Of Canada cut their price objective on Aardvark Therapeutics from $20.00 to $19.00 and set an "outperform" rating on the stock in a research report on Thursday, August 14th. HC Wainwright assumed coverage on Aardvark Therapeutics in a report on Monday, June 30th. They issued a "buy" rating and a $40.00 target price on the stock. Wall Street Zen lowered Aardvark Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, June 14th. Finally, Bank of America dropped their target price on Aardvark Therapeutics from $26.00 to $25.00 and set a "buy" rating on the stock in a report on Thursday, August 28th. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Aardvark Therapeutics has an average rating of "Buy" and a consensus target price of $32.60.

Hedge Funds Weigh In On Aardvark Therapeutics

Hedge funds have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of Aardvark Therapeutics during the second quarter worth about $42,000. Walleye Capital LLC purchased a new position in shares of Aardvark Therapeutics during the first quarter worth about $88,000. New York State Common Retirement Fund purchased a new position in shares of Aardvark Therapeutics during the second quarter worth about $99,000. Bank of America Corp DE grew its holdings in shares of Aardvark Therapeutics by 72.9% during the second quarter. Bank of America Corp DE now owns 7,989 shares of the company's stock worth $108,000 after buying an additional 3,369 shares during the last quarter. Finally, Goldman Sachs Group Inc. purchased a new position in shares of Aardvark Therapeutics during the first quarter worth about $153,000.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.